Quebec · CCAA
Deuxième rapport du Contrôleur portant sur l'état des affaires et des finances des Débitrices (Caviardé) - 2024-02-07
Court officer report · 7 February 2024 · French
AI summary
A plain-English summary drawn only from this filing: what it is, why it matters, and the parties, amounts and dates it turns on.
What we verified from this filing4 verified
- process resultsndas: 15 · note: Nine parties visited the facilities. No offers were submitted before the June 15, 2023 deadline; LOIs and IOIs were received between July 7 and 10, 2023 (no count given). · as of: 2023-06-15 · solicited: 36
- purchaserprice: note: Price not stated in the report; the summary of the Second Purchase Agreement is redacted (caviardée) · sealed: true · scope: 100 % des actions en circulation de Brunswick Health Group inc. et de Brunswick Labs and Tests inc. (medical activities of the Brunswick Group), by reverse vesting · status: proposed · name note: Unnamed 'Acheteur' (the Purchaser) under the Purchase Agreement and Second Purchase Agreement; the operative text of the report never names it · structure: shares · name source: operative · relationship: unstated · agreement date: 2024-01-31
- sale advisorPricewaterhouseCoopers Corporate Finance inc.
- sale outcometext: The Second Purchase Agreement, a reverse vesting transaction, was signed January 31, 2024 and closed in escrow, subject to court approval of the Second Purchase Agreement and the contemplated transaction; the Monitor seeks the approval and vesting order. · scope: whole_business · status: pending_approval